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Abstract
Background: The International Carotid Stenting Study was a multicenter randomized trial in which patients with
symptomatic carotid artery stenosis were randomly allocated to treatment by carotid stenting or endarterectomy.
Economic evidence comparing these treatments is limited and inconsistent.
Aims: We compared the cost-effectiveness of stenting versus endarterectomy using International Carotid Stenting
Study data.
Methods: We performed a cost-utility analysis estimating mean costs and quality-adjusted life years per patient for both
treatments over a five-year time horizon based on resource use data and utility values collected in the trial. Costs of managing
stroke events were estimated using individual patient data from a UK population-based study (Oxford Vascular Study).
Results: Mean costs per patient (95% CI) were US$10,477 ($9669 to $11,285) in the stenting group (N¼ 853) and
$9669 ($8835 to $10,504) in the endarterectomy group (N¼ 857). There were no differences in mean quality-adjusted
life years per patient (3.247 (3.160 to 3.333) and 3.228 (3.150 to 3.306), respectively). There were no differences in
adjusted costs between groups (mean incremental costs for stenting versus endarterectomy $736 (95% CI –$353 to
$1826)) or adjusted outcomes (mean quality-adjusted life years gained 0.010 (95% CI 0.117 to 0.097)). The incre-
mental net monetary benefit for stenting versus endarterectomy was not significantly different from zero at the max-
imum willingness to pay for a quality-adjusted life year commonly used in the UK. Sensitivity analyses showed little
uncertainty in these findings.
Conclusions: Economic considerations should not affect whether patients with symptomatic carotid stenosis undergo
stenting or endarterectomy.
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Introduction
Stroke is a leading cause of mortality and disability
worldwide.1 In the UK, there are 152,000 strokes and
49,000 stroke deaths each year. UK total annual health
care costs of stroke are £1.8 billion (1% health care
expenditure), and total annual societal costs are £3.7
billion.2 Carotid stenosis causes about 10% of all ische-
mic strokes. Elective treatment of carotid stenosis by
surgical endarterectomy or carotid artery stenting can
prevent future stroke. The International Carotid
Stenting Study (ICSS) was the largest randomized
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trial comparing stenting with endarterectomy for treat-
ment of symptomatic carotid stenosis.3–5 ICSS was an
international multicenter randomized clinical trial in
which 1710 patients with symptomatic carotid stenosis
were recruited and followed at 50 centers in Europe,
Australia, New Zealand and Canada between May
2001 and October 2008. Participants were randomly
assigned to stenting (n¼ 853) or endarterectomy
(n¼ 857), and followed for up to 10 years. The study
found that long-term functional outcome and the risk
of fatal or disabling stroke in patients with symptom-
atic carotid stenosis treated by stenting and endarterec-
tomy were similar, concluding that stenting is an
appropriate treatment choice for patients with symp-
tomatic carotid stenosis if the risk of peri-procedural
stroke is low.4,5 The trial also showed an excess of pro-
cedural stroke (mainly non-disabling strokes) within 30
days of stenting compared to endarterectomy, while
endarterectomy was associated with an excess of cranial
nerve palsy and wound hematoma at time of surgery.
The impact of these events on health care costs and
quality of life was uncertain. Given the large number
of patients eligible for these procedures, their cost
and cost-eﬀectiveness has implications for treatment
selection. There have been several economic analyses
of stenting versus endarterectomy for carotid stenosis,
but many are observational or modelling studies with
short time horizons; conclusions are mixed (Supporting
Information).
Aims
We investigated the cost and cost-eﬀectiveness of stent-
ing versus endarterectomy using ICSS data.
Methods
Overview of economic evaluation
See Supporting Information for background details
about ICSS. We undertook a cost-utility analysis
to compare the costs and outcomes of stenting and
endarterectomy for the 1710 patients in the intention-
to-treat sample of ICSS. The outcome measure was
quality-adjusted life years (QALYs), which combine
length of life and quality of life, based on National
Institute for Health and Care Excellence (NICE) rec-
ommendations.6 Cost-eﬀectiveness was expressed as
incremental net monetary beneﬁts (NMBs).6 The ana-
lysis took a UK National Health Service (NHS) and
personal social services (PSS) perspective.6 Resource
use data were included from all participating centers
and UK unit costs were applied. Costs were calculated
in 2013/14 UK£ and are presented in 2013/14 US$
using a purchasing power parity of £1¼ $1.43.7 The
time horizon was ﬁve years, reﬂecting average follow-
up in the trial. Extrapolation beyond the end of the trial
was not undertaken because the within-trial analysis
found no evidence of signiﬁcant diﬀerences in costs or
beneﬁts between groups; ﬁve years was long enough to
reﬂect all important diﬀerences in costs or outcomes
between treatments. An annual discount rate of 3.5%
was applied to costs and outcomes.6
Resource use and costs
For every patient we calculated the cost of the index
procedure and of follow-up based on resource use data
from the trial. Costs included: surgeon and radiologist
time; operating theatre time including nursing staﬀ,
drugs, consumables and overheads; anesthesia; mater-
ials and devices including stents, shunts, patches, cere-
bral protection devices, catheters, wires and sheaths;
length of hospital stay in the intensive care unit (ICU)
and inpatient ward; additional procedures; complica-
tions within 30 days of index procedure (fatal
and non-fatal myocardial infarction, severe hematoma,
disabling cranial nerve palsy); imaging tests (nine
types); drug treatment (six types); and subsequent
non-disabling, disabling or fatal strokes.
Unit costs were obtained from published sources8–13
and local costs, inﬂated where appropriate.8 Unit costs
of surgeon, radiologist and operating theatre time were
hourly costs applied to procedure durations collected
during the trial. Choice of stents was at the discretion of
the interventionist. In the base case analysis each stent
was assigned an acquisition cost of $1199 based on the
local cost of the most commonly used stent (Carotid
Wallstent, Boston Scientiﬁc); this was varied in sensi-
tivity analysis. Unit costs of hospital stays were daily
costs applied to length of stay data collected in the trial.
Length of stay in days on the ICU was not collected for
individual patients, but mean values were collected by
center. We assumed patients admitted to the ICU post-
operatively stayed for one day. Costs of additional car-
otid artery procedures were assumed to be equal to the
mean cost of the index procedures. Costs of drug treat-
ment were monthly costs applied to treatment dur-
ations collected in the trial. Stroke events were
recorded in the trial, but the costs of managing them
were not. These were obtained from supplementary
analyses of a contemporaneous UK population-based
study of all strokes, the Oxford Vascular (OXVASC)
Study,14,15 including over 1000 consenting transient
ischemic attack or stroke patients recruited from 1
April 2002 to 31 March 2007 in nine general practices
across Oxfordshire, UK and followed for up to 60
months. These data were used to predict care home
and hospital care costs for each stroke patient as a
function of their sex, age, disability before stroke,
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previous history of cardiovascular disease, stroke sever-
ity and recurrent strokes. See Supporting Information
for further details about the analysis of OXVASC data.
Utilities and QALYs
Generic health status was described at baseline (random-
ization), one and six months, and one, two, three, four,
and ﬁve years post-randomization using the EQ-5D-3L
descriptive system.16,17 EQ-5D-3L health states were
converted into utility values using a formula that
attaches weights to each level in each dimension based
on valuations by general population samples. We used a
value set for theUKpopulation to calculate utility values
at each time point for every participant.18 Utility values
of one represent full health, values of zero are equivalent
to death, negative values represent states worse than
death. Patients who died were assigned a utility value
of zero at their date of death. A utility proﬁle was con-
structed for every patient assuming a straight line rela-
tion between their utility values at each measurement
point. QALYs for every patient from baseline to ﬁve
years were calculated as the area under the utility proﬁle.
Dealing with missing data
The extent of missing data across all of the individual
variables in the analysis ranged from 0% to 64%
(Supplementary Information). Multiple imputation
was used to impute missing data for every patient up
to ﬁve years for cost of: surgeon time; radiologist time;
operating theatre time; anesthesia; stents; shunts;
patches; cerebral protection devices; other materials
used in stenting; length of hospital stay; non-fatal myo-
cardial infarction; imaging test; drug treatment; and,
strokes; plus, total cost; utility values at every time
point; and total QALYs. Age, sex, study center and
treatment allocation were included in the imputation
as additional explanatory variables. We used an itera-
tive Markov chain Monte Carlo procedure based on
multivariate normal regression, generating 20 imputed
datasets.
Statistical methods
Mean costs, outcomes and NMBs were compared
between all patients randomly assigned to stenting
and endarterectomy, irrespective of which treatment
was administered and whether or not they received add-
itional carotid artery procedures. We calculated diﬀer-
ences in mean costs, QALYs and incremental NMBs
between groups. NMBs for stenting (S) and endarter-
ectomy (E) were calculated as the mean QALYs per
patient (Q) multiplied by the maximum willingness
to pay for a QALY (R) minus the mean cost per
patient (C), i.e., NMBi¼QiRCi for i¼S, E. The
incremental NMB (iNMB) was calculated as the diﬀer-
ence in mean QALYs per patient with stenting versus
endarterectomy multiplied by the maximum willingness
to pay for a QALY minus the diﬀerence in mean cost
per patient, i.e., iNMB¼ (QSQE)R (CSCE).
We used the cost-eﬀectiveness threshold range recom-
mended by NICE (£20,000 (approximately $29,000) to
£30,000 ($43,000)6) as the lower and upper limits of the
maximum willingness to pay for a QALY (R). If the
incremental NMB is positive (negative) then stenting
(endarterectomy) is preferred on cost-eﬀectiveness
grounds. QALYs gained were adjusted for age, sex,
study center and baseline utility values using regression
analysis; incremental costs were adjusted for age, sex
and study center. For each of the 20 imputed datasets
we ran 1000 bootstrap replications using non-para-
metric bootstrapping, resampling observations with
replacement. Results were combined using equations
described by Briggs et al.19 to calculate standard
errors around mean values accounting for uncertainty
in imputed values, skewness of cost and utility data,
and sampling variation. Standard errors were used to
calculate 95% CIs around point estimates.
Sensitivity and sub-group analyses
A cost-eﬀectiveness acceptability curve20 showing the
probability that stenting was cost-eﬀective compared
with endarterectomy at a range of values for the max-
imum willingness to pay for a QALY was generated
based on the proportion of the bootstrap replications
across all 20 imputed datasets with positive incremental
NMBs.21 The probability that stenting was cost-
eﬀective at a maximum willingness to pay for a
QALY of $29,000 and $43,000 was based on the pro-
portion of bootstrap replications with positive incre-
mental NMBs at these values. We undertook further
sensitivity analyses: no adjustment for potential con-
founders; complete case analysis without imputing
missing values; univariate analyses of high and low
values for each cost component (50% higher and
lower than the base case); and discount rate (1.5%,
5%). No signiﬁcant interactions were found in any
sub-group analyses of the primary outcomes in ICSS.
In post hoc sub-group analyses we investigated cost-
eﬀectiveness by sex and baseline age (70, <70 years).
Results
See Supporting Information for the resource use and
unit cost data used in the analysis. Accounting for miss-
ing data, mean total costs per patient (95% CI) were
$10,477 ($9669 to $11,285) in the stenting group
(N¼ 853) and $9669 ($8835 to $10,504) in the
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endarterectomy group (N¼ 857; Table 1). In both
groups, approximately two-thirds of the total costs
were for the index procedure and one-third for
follow-up. Values were similar in the complete case
analysis (Supporting Information Table S5).
Mean utility values at each follow-up point were
similar for the two groups and there was a decline
over time (Table 1). Mean total QALYs per patient
were 3.228 (3.150 to 3.306) in the endarterectomy
group and 3.247 (3.160 to 3.333) in the stenting
group. Values were similar for complete cases
(Supporting Information).
Mean NMBs for endarterectomy and stenting were
$82,478 ($79,832 to $85,124) and $82,262 ($79,447 to
$85,077) at a maximum willingness to pay for a QALY
of $29,000, and $128,551 ($124,774 to $132,328) and
$128,632 ($124,580 to $132,684) at a maximum willing-
ness to pay for a QALY of $43,000 (Table 1).
There were no signiﬁcant diﬀerences in costs
between the two groups (mean incremental costs for
stenting versus endarterectomy $736 (95% CI $353
to $1826)) or in outcomes (mean QALYs gained
0.010 (95% CI 0.117 to 0.097); Table 2). The incre-
mental NMB for stenting versus endarterectomy was
not signiﬁcantly diﬀerent from zero at a maximum will-
ingness to pay for a QALY of $29,000 (mean $991,
95% CI $4475 to $2494) or $43,000 (mean $1118,
95% CI $6110 to $3875).
At a maximum willingness to pay for a QALY of
$29,000 ($43,000) the probability that stenting is cost-
eﬀective was 0.27 (0.31; Table 2, Figure 1). Incremental
costs, QALYs gained and incremental NMBs for stent-
ing versus endarterectomy remained not signiﬁcantly
diﬀerent from zero when re-running the analysis with-
out adjustment, and using complete cases (Table 2).
The incremental NMB was most sensitive to the cost
of stents (Figure 2), but in every case it was not signiﬁ-
cantly diﬀerent from zero. In all sub-groups the incre-
mental costs, QALYs gained and incremental NMBs
were not signiﬁcantly diﬀerent from zero, though in
Table 1. Mean utility values, QALYs and costs per patient
Endarterectomy (N¼ 857) Stenting (N¼ 853)
Mean (95% CI) Mean (95% CI)
Cost of index procedure 6499 (6171, 6828) 6820 (6463, 7177)
Cost of follow-upa 3170 (2466, 3870) 3657 (3032, 4283)
Total cost 9669 (8835, 10,504) 10,477 (9669, 11,285)
Utility values
Baseline 0.758 (0.743, 0.774) 0.776 (0.761, 0.790)
1 month 0.779 (0.763, 0.795) 0.777 (0.759, 0.795)
6 months 0.763 (0.746, 0.780) 0.754 (0.735, 0.773)
1 year 0.739 (0.721, 0.758) 0.737 (0.718, 0.757)
2 years 0.709 (0.688, 0.729) 0.710 (0.689, 0.732)
3 years 0.677 (0.655, 0.699) 0.674 (0.650, 0.698)
4 years 0.628 (0.602, 0.653) 0.648 (0.622, 0.675)
5 years 0.594 (0.563, 0.625) 0.609 (0.578, 0.641)
QALYs 3.228 (3.150, 3.306) 3.247 (3.160, 3.333)
Net monetary benefit
$29,000 82,478 (79,832, 85,124) 82,262 (79,447, 85,077)
$43,000 128,551 (124,774, 132,328) 128,632 (124,580, 132,684)
QALY: quality-adjusted life year; CI: confidence interval.
Note: Costs are in 2013/14 US$. Data include values imputed using multiple imputation (see text).
aFollow-up to five years for every patient.
International Journal of Stroke, 0(0)
4 International Journal of Stroke 0(0)
T
a
b
le
2
.
In
cr
e
m
e
n
ta
l
co
st
-e
ff
e
ct
iv
e
n
e
ss
o
f
st
e
n
ti
n
g
vs
.
e
n
d
ar
te
re
ct
o
m
y
In
cr
e
m
e
n
ta
l
co
st
Q
A
LY
s
ga
in
e
d
In
cr
e
m
e
n
ta
l
n
e
t
m
o
n
e
ta
ry
b
e
n
e
fit
P
ro
b
ab
ili
ty
st
e
n
ti
n
g
co
st
-e
ff
e
ct
iv
e
$
2
9
,0
0
0
$
4
3
,0
0
0
M
e
an
(9
5
%
C
I)
M
e
an
(9
5
%
C
I)
M
e
an
(9
5
%
C
I)
M
e
an
(9
5
%
C
I)
$
2
9
,0
0
0
$
4
3
,0
0
0
B
as
e
ca
se
a
7
3
6
(
3
5
3
,
1
8
2
6
)
0
.0
1
0
(
0
.1
1
7
,
0
.0
9
7
)
9
9
1
(
4
4
7
5
,
2
4
9
4
)
1
1
1
8
(
6
1
1
0
,
3
8
7
5
)
0
.2
7
0
.3
1
N
o
ad
ju
st
m
e
n
tb
8
0
8
(
2
9
9
,
1
9
1
5
)
0
.0
1
9
(
0
.0
9
8
,
0
.1
3
5
)
2
1
5
(
4
0
2
7
,
3
4
1
9
)
8
1
(
5
3
6
9
,
5
2
9
9
)
0
.4
3
0
.4
9
C
o
m
p
le
te
ca
se
an
al
ys
is
c
7
6
1
(
1
1
9
3
,
2
7
1
5
)
0
.0
0
6
(
0
.1
9
4
,
0
.2
0
6
)
5
9
2
(
6
6
6
5
,
5
4
8
2
)
5
0
7
(
9
3
3
3
,
8
3
1
8
)
0
.4
2
0
.4
5
Su
b
-g
ro
u
p
an
al
ys
e
sd
M
e
n
4
8
1
(
6
7
2
,
1
6
3
4
)
0
.0
5
5
(
0
.1
8
5
,
0
.0
7
6
)
2
0
4
3
(
6
1
0
7
,
2
0
2
3
)
2
8
2
2
(
8
7
0
2
,
3
0
5
8
)
0
.1
7
0
.1
8
W
o
m
e
n
1
1
2
3
(
1
1
5
3
,
3
4
0
0
)
0
.1
0
3
(
0
.0
9
8
,
0
.3
0
4
)
1
7
9
3
(
4
7
5
9
,
8
3
7
1
)
3
2
7
0
(
6
0
4
4
,
1
2
,5
8
3
)
0
.7
1
0
.7
5
A
ge
7
0
ye
ar
s
1
1
1
2
(
4
6
1
,
2
6
8
5
)
0
.0
6
1
(
0
.2
1
9
,
0
.0
9
7
)
2
8
4
5
(
7
8
1
4
,
2
1
2
6
)
3
7
1
0
(
1
0
,8
5
9
,
3
4
3
7
)
0
.1
3
0
.1
6
A
ge
<
7
0
ye
ar
s
2
0
4
(
1
0
1
8
,
1
4
2
6
)
0
.0
5
7
(
0
.0
9
4
,
0
.2
0
8
)
1
4
1
6
(
3
1
8
9
,
6
0
2
3
)
2
2
2
7
(
4
4
8
1
,
8
9
3
5
)
0
.7
3
0
.7
5
Q
A
LY
:
q
u
al
it
y-
ad
ju
st
e
d
lif
e
ye
ar
;
C
I:
co
n
fid
e
n
ce
in
te
rv
al
.
N
o
te
:
C
o
st
s
ar
e
in
2
0
1
3
/1
4
U
S$
.
a
D
at
a
in
cl
u
d
e
va
lu
e
s
im
p
u
te
d
u
si
n
g
m
u
lt
ip
le
im
p
u
ta
ti
o
n
(s
e
e
te
x
t)
.
T
h
e
Q
A
LY
s
ga
in
e
d
,
in
cr
e
m
e
n
ta
l
co
st
an
d
in
cr
e
m
e
n
ta
l
n
e
t
m
o
n
e
ta
ry
b
e
n
e
fit
fig
u
re
s
ar
e
fo
r
st
e
n
ti
n
g
m
in
u
s
e
n
d
ar
te
re
ct
o
m
y
an
d
ar
e
ad
ju
st
e
d
fo
r
p
o
te
n
ti
al
co
n
fo
u
n
d
e
rs
(s
e
e
te
x
t)
.
b
A
s
fo
r
th
e
b
as
e
ca
se
an
al
ys
is
e
x
ce
p
t
th
e
Q
A
LY
s
ga
in
e
d
an
d
th
e
in
cr
e
m
e
n
ta
l
co
st
s
ar
e
u
n
ad
ju
st
e
d
.
c
A
s
fo
r
th
e
b
as
e
ca
se
an
al
ys
is
e
x
ce
p
t
th
e
re
is
n
o
m
u
lt
ip
le
im
p
u
ta
ti
o
n
o
f
m
is
si
n
g
va
lu
e
s
an
d
th
e
9
5
%
co
n
fid
e
n
ce
in
te
rv
al
s
w
e
re
d
e
ri
ve
d
fr
o
m
1
0
0
0
b
o
o
ts
tr
ap
re
p
lic
at
io
n
s
o
f
a
si
n
gl
e
d
at
as
e
t
co
n
ta
in
in
g
th
e
N
¼
2
0
2
e
n
d
ar
te
re
ct
o
m
y
p
at
ie
n
ts
an
d
N
¼
2
5
4
st
e
n
ti
n
g
p
at
ie
n
ts
w
it
h
n
o
m
is
si
n
g
va
lu
e
s.
d
A
s
fo
r
th
e
b
as
e
ca
se
an
al
ys
is
b
u
t
ru
n
o
n
p
at
ie
n
ts
w
it
h
in
e
ac
h
su
b
-g
ro
u
p
.
A
m
o
n
g
th
e
N
¼
8
5
7
e
n
d
ar
te
re
ct
o
m
y
p
at
ie
n
ts
6
0
6
ar
e
m
e
n
,
2
5
1
ar
e
w
o
m
e
n
,4
5
3
ar
e
ag
e
7
0
an
d
4
0
4
ar
e
<
7
0
.A
m
o
n
g
th
e
N
¼
8
5
3
st
e
n
ti
n
g
p
at
ie
n
ts
th
e
fig
u
re
s
ar
e
6
0
1
,
2
5
2
,
4
5
8
an
d
3
9
5
.
International Journal of Stroke, 0(0)
Morris et al. 5
men and those aged 70 years the probability that
stenting is cost-eﬀective compared with endarterectomy
was lower than for women and those aged <70 years.
Discussion
Our economic analysis of the ICSS showed that
stenting and endarterectomy had similar costs and
outcomes. This was despite the ﬁnding in ICSS of
higher rates of non-disabling strokes in the stenting
group. Sensitivity analyses showed little uncertainty
in this ﬁnding. The ﬁndings mean there is no
reason to prefer stenting or endarterectomy on the
basis of diﬀerences in quality of life or on economic
grounds; other factors should be taken into account
when deciding which option to use to treat patients
with symptomatic carotid stenosis, e.g., imaging fea-
tures or age.
Previous economic analyses of stenting versus end-
arterectomy are mainly small single-center observa-
tional cost studies with limited consideration of costs;
they have drawn varying conclusions (see Supporting
Information for a detailed review). Only one other ran-
domized trial, the North-American-based CREST, has
reported an economic analysis; this also found evidence
of no diﬀerences in costs and QALYs between stenting
and endarterectomy.22 CREST included patients with
asymptomatic stenosis, which has a much lower rate of
procedural stroke that might have inﬂuenced the
analysis.
The main strength of our analysis is that it is based
on a large international multicenter randomized trial
with detailed information on resource use, utility
values and mortality for a median follow-up period of
4.2 years. There are several limitations. First, data on
costs of managing strokes were not collected in the
trial. Rather than applying the same unit cost to
every stroke, we used individual patient data of the
OXVASC Study to predict stroke costs at the patient-
level. These were detailed contemporaneous UK-
speciﬁc costs matched to patients in the trial, but are
not the actual costs incurred. When we adjusted these
costs in sensitivity analyses the ﬁndings did not change.
Second, the analysis took a UK NHS/PSS perspective.
Results may diﬀer between countries depending on the
relative value of unit costs (e.g., cost of stents). Third, a
wider perspective (e.g., societal) could have been taken,
including costs to patients, families and businesses.
Given the trial found no diﬀerences in mortality or dis-
ability it is unlikely this would aﬀect the incremental
costs. Fourth, the time horizon was ﬁve years. We
could have taken a longer time horizon, but there
were no diﬀerences in costs or beneﬁts between
groups at this point so this would not have aﬀected
the incremental analyses. Fifth, we did not have com-
plete data for every participant in the trial and used
Figure 1. Cost-effectiveness acceptability curve showing the probability that stenting is cost-effective vs. endarterectomy at
different values of the maximum willingness to pay for a QALY.
QALY: quality adjusted life year.
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multiple imputation. Conclusions were the same for
analyses using multiple imputation and complete
cases. Sixth, ICSS started in the early days of carotid
stenting, and stents and protection devices have also
evolved since the trial started. It is possible that the
costs and outcomes are not representative of routine
clinical practice today.
ICSS showed that long-term functional outcome and
the risk of fatal or disabling stroke of patients with
symptomatic carotid stenosis allocated treatment by
stenting is similar to endarterectomy. Our accompanying
economic analysis has shown that despite stenting in the
trial being associated with an excess of stroke, this did
not translate into diﬀerences in quality of life or costs.
Authors’ note
For a list of ICSS investigators see International Carotid
Stenting Study Investigators.4
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